Table 3. Multivariate analysis for progression-free survival (PFS) and overall survival (OS).

Variables		PFS (95% CI)	OS (95% CI)
Pretreatment NLR
	<3.81	1.00	1.00
	>3.81	1.25 (0.86–1.83)	1.89 (1.11–3.24)
NLR change
	Maintained	1.00	1.00
	Increased	2.07 (1.32–3.25)	1.56 (0.84–2.91)

Adjustment for age, histology, American Society of Anesthesiologists, carbohydrate antigen-125, International Federation of Gynecology and Obstetrics stage, residual disease, and total cycles of chemotherapy.

CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio.